Published in Ann Oncol on November 01, 1993
Salivary gland carcinomas. Oral Maxillofac Surg (2012) 1.20
Adenoid cystic carcinoma of nasal cavity - a case report. Indian J Otolaryngol Head Neck Surg (2003) 1.05
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head Neck (2009) 0.92
Concern Systemic therapy in the management of metastatic or advanced salivary gland cancers. Head Neck Oncol (2012) 0.86
Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis. J Cancer Res Clin Oncol (2005) 0.84
Activity of chemotherapy in the palliative treatment of salivary gland tumors: review of the literature. Eur Arch Otorhinolaryngol (2007) 0.82
Management of unresectable head and neck cancers - a retrospective analysis at a rural medical college of India. Indian J Otolaryngol Head Neck Surg (2010) 0.78
A Phase II study of Dovitinib in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Clin Cancer Res (2017) 0.75
Nedaplatin as a Single-Agent Chemotherapy May Support Palliative Therapy for Patients with Adenoid Cystic Carcinoma: A Case Report. Case Rep Oncol (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet (2001) 6.11
Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med (1992) 5.14
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer (2001) 4.49
Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst (1996) 4.22
Cancer in the elderly: why so badly treated? Lancet (1990) 3.67
Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst (1998) 3.67
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer (2002) 3.26
Cervical lymph node metastasis: assessment of radiologic criteria. Radiology (1990) 3.24
RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer (2006) 3.15
Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med (1987) 3.04
[Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression]. Ned Tijdschr Geneeskd (2006) 2.65
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res (2001) 2.64
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol (2001) 2.52
The size of lymph nodes in the neck on sonograms as a radiologic criterion for metastasis: how reliable is it? AJNR Am J Neuroradiol (1998) 2.48
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet (1997) 2.33
Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol (2000) 2.20
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst (1999) 2.15
High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group. Eur J Cancer (1995) 2.10
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res (1999) 2.06
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2001) 1.99
Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer (1994) 1.98
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer (2001) 1.91
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer (1997) 1.88
Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer (1993) 1.82
Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer (2001) 1.82
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol (2002) 1.80
Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer (1994) 1.79
Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. Ann Oncol (2002) 1.78
Amino acid propensities for the collagen triple-helix. Biochemistry (2000) 1.78
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol (2000) 1.77
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer (2003) 1.75
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer (2003) 1.70
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res (2000) 1.70
RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer (2005) 1.69
Inherited susceptibility to bleomycin-induced chromatid breaks in cultured peripheral blood lymphocytes. J Natl Cancer Inst (1999) 1.68
Prognostic factors of neck node metastasis. Clin Otolaryngol Allied Sci (1982) 1.67
The molecular genetics of human lung cancer. Eur Respir J (1989) 1.64
Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst (1991) 1.64
Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol (1995) 1.61
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol (1998) 1.61
Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res (2001) 1.60
Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. Eur J Cancer (2005) 1.60
Destabilization of osteogenesis imperfecta collagen-like model peptides correlates with the identity of the residue replacing glycine. Proc Natl Acad Sci U S A (2000) 1.58
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer (1996) 1.58
Role of formulation vehicles in taxane pharmacology. Invest New Drugs (2001) 1.58
Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. Clin Cancer Res (2000) 1.57
Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer (2008) 1.57
Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res (1993) 1.56
Comparative pathology of prevalent and incident cancers detected by breast screening. Edinburgh Breast Screening Project. Lancet (1986) 1.56
Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size. Ann Oncol (1994) 1.56
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol (1994) 1.56
Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther (2008) 1.54
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) Clin Cancer Res (1999) 1.54
miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene (2012) 1.54
The impact of nutritional status on the prognoses of patients with advanced head and neck cancer. Cancer (1999) 1.53
Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med (2000) 1.52
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer (1997) 1.52
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours. Br J Cancer (1998) 1.51
The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-cell adhesion. J Cell Biol (1995) 1.51
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer (2003) 1.50
Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol (1991) 1.49
Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support. J Natl Cancer Inst (1996) 1.49
Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer (1991) 1.47
A phase II trial of vinorelbine and thiotepa in metastatic breast cancer. Ann Oncol (1995) 1.46
Pharmacokinetically guided dosing for intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma. Eur J Cancer (1992) 1.45
A domain of human immunodeficiency virus type 1 Vpr containing repeated H(S/F)RIG amino acid motifs causes cell growth arrest and structural defects. Proc Natl Acad Sci U S A (1995) 1.43
Screening for distant metastases in patients with head and neck cancer. Laryngoscope (2000) 1.42
Potential early markers of carcinogenesis in the mucosa of the head and neck using exfoliative cytology. J Pathol (1996) 1.42
Peripheral neurotoxicity induced by docetaxel. Neurology (1996) 1.42
At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies. Ann Oncol (1999) 1.41
[Paraneoplastic syndromes in three patients with renal cell carcinoma]. Ned Tijdschr Geneeskd (2004) 1.41
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer (2002) 1.41
[Continuous intrathecal injection of baclofen in generalized tetanus. A therapeutic alternative]. Presse Med (1997) 1.39
[Development and results of surgical treatment of pleomorphic adenoma of the parotid gland in 245 patients, 1974-1994]. Ned Tijdschr Geneeskd (1996) 1.39
Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol (2001) 1.38